Research programme: PEGylated recombinant interleukin-11 protein - ViroMed

Drug Profile

Research programme: PEGylated recombinant interleukin-11 protein - ViroMed

Alternative Names: NL 002 1; PEG-VM 501

Latest Information Update: 27 May 2013

Price : $50

At a glance

  • Originator ViroMed Co Ltd
  • Developer ViroMed
  • Class Interleukins; Recombinant proteins
  • Mechanism of Action Haematopoiesis stimulants; Interleukin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Thrombocytopenia

Highest Development Phases

  • Preclinical Thrombocytopenia

Most Recent Events

  • 27 May 2013 PEG-VM501 is available for licensing worldwide (excluding China) once it enters clinical development. http://viromed.co.kr/
  • 01 May 2013 Preclinical development is ongoing in South Korea
  • 17 Jun 2010 Preclinical trials in Thrombocytopenia (chemotherapy-induced) in South Korea (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top